Menaquinone-4(Synonyms: Vitamin K2(MK-4); Menaquinone K4)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Menaquinone-4 (Synonyms: Vitamin K2(MK-4); Menaquinone K4) 纯度: ≥98.0%

Menaquinone-4 (Vitamin K2(MK-4)) 是一种维生素 K,用作一种止血剂,有潜力用于骨质疏松的研究。

Menaquinone-4(Synonyms: Vitamin K2(MK-4);  Menaquinone K4)

Menaquinone-4 Chemical Structure

CAS No. : 863-61-6

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥550 In-stock
100 mg ¥500 In-stock
250 mg ¥800 In-stock
1 g ¥2312 In-stock
5 g   询价  
10 g   询价  

* Please select Quantity before adding items.

Menaquinone-4 相关产品

相关化合物库:

  • Natural Product Library Plus
  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Metabolism/Protease Compound Library
  • Natural Product Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Human Endogenous Metabolite Compound Library
  • Drug Repurposing Compound Library
  • NMPA-Approved Drug Library
  • FDA Approved & Pharmacopeial Drug Library
  • Gut Microbial Metabolite Library
  • Food-Sourced Compound Library

生物活性

Menaquinone-4 is a vitamin K, used as a hemostatic agent, and also a adjunctive therapy for the pain of osteoporosis.

IC50 & Target

Human Endogenous Metabolite

 

体外研究
(In Vitro)

Menaquinone-4 (MK-4, 0, 1, 5, 10 μM) increases the ALP activity in Caco-2 cells. Menaquinone-4 (1 μM) significantly increases intensities of hSI expression[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Menaquinone-4 (K2, 0.2 g/kg diet) in HF-K2 group produces epididymal fat in C57BL/6J mice, and also increases the bone density of mice[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

444.65

Formula

C31H40O2

CAS 号

863-61-6

中文名称

甲萘醌 4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据
In Vitro: 

DMSO : 20 mg/mL (44.98 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.2490 mL 11.2448 mL 22.4896 mL
5 mM 0.4498 mL 2.2490 mL 4.4979 mL
10 mM 0.2249 mL 1.1245 mL 2.2490 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.68 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2 mg/mL (4.50 mM); Suspended solution; Need ultrasonic

    此方案可获得 2 mg/mL (4.50 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2 mg/mL (4.50 mM); Clear solution

    此方案可获得 ≥ 2 mg/mL (4.50 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Noda S, et al. Menaquinone-4 (vitamin K2) up-regulates expression of human intestinal alkaline phosphatase in Caco-2 cells. Nutr Res. 2016 Nov;36(11):1269-1276.

    [2]. Kim M, et al. Vitamin K1 (phylloquinone) and K2 (menaquinone-4) supplementation improves bone formation in a high-fat diet-induced obese mice. J Clin Biochem Nutr. 2013 Sep;53(2):108-13.

Cell Assay
[1]

Caco-2 cells are plated at a density of 2-5 × 104 cells/cm2 onto a 35-mm dish. Cells are incubated for 2 to 3 days until 60%-70% confluency, and desired concentrations of Menaquinone-4 (0, 1.0, 5.0, and 10.0 μM) are added. The final concentration of the vehicle is 0.1% of the culture medium, and the culture medium is changed twice a week. Cells are assayed on days 0, 3, 7, and 11 after the addition of Menaquinone-4[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2]

Forty-two male, 4-week-old C57BL/6J mice provided with feed and drink ad libitum. For environmental adaptation, the animals had 1 week of circulation, and then are provided with the experimental diet after being randomly divided into 6 groups (7 animals in each group; randomized block design). The AIN-93G diets consist of a normal diet (N), normal diet + vitamin K1 (N-K1), normal diet + vitamin Menaquinone-4 (N-K2), 45% high-fat diet (HF), 45% high-fat diet + vitamin K1 (HF-K1), and a 45% high-fat diet + vitamin Menaquinone-4 (HF-K2). The vitamin K1 and vitamin Menaquinone-4 contents are 200 mg/1,000 g, and the diet is provided in pellet form. Body weight is measured once a week, and the food efficiency ratio (FER) is calculated by dividing the increased body weight from day 1 to the final day by the food intake amount during the experiment period. For fat amount measurement, the epididymal fat, perirenal fat, and retroperitoneal fat are extracted from dead animal subjects, are washed with 0.9% NaCl, dried by filter paper, and then are weighed[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Noda S, et al. Menaquinone-4 (vitamin K2) up-regulates expression of human intestinal alkaline phosphatase in Caco-2 cells. Nutr Res. 2016 Nov;36(11):1269-1276.

    [2]. Kim M, et al. Vitamin K1 (phylloquinone) and K2 (menaquinone-4) supplementation improves bone formation in a high-fat diet-induced obese mice. J Clin Biochem Nutr. 2013 Sep;53(2):108-13.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务